Free Trial

Scancell (LON:SCLP) Stock Price Passes Below 200 Day Moving Average - Time to Sell?

Scancell logo with Medical background

Scancell Holdings plc (LON:SCLP - Get Free Report)'s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 10.75 ($0.14) and traded as low as GBX 10 ($0.13). Scancell shares last traded at GBX 11.65 ($0.16), with a volume of 2,178,450 shares.

Scancell Price Performance

The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The firm has a market capitalization of £124.29 million, a P/E ratio of -18.40 and a beta of 0.35. The company's 50 day moving average price is GBX 8.88 and its 200 day moving average price is GBX 10.68.

Scancell (LON:SCLP - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter. As a group, sell-side analysts anticipate that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.

About Scancell

(Get Free Report)

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

See Also

Should You Invest $1,000 in Scancell Right Now?

Before you consider Scancell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.

While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines